Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oil palm phenolics (OPP) is a water-soluble, bioactive-rich extract derived from the aqueous byproduct of palm oil milling, known as palm oil mill effluent (POME). Developed primarily by the Malaysian Palm Oil Board (MPOB), OPP is characterized by a high concentration of phenolic acids, notably caffeoylshikimic acid, p-hydroxybenzoic acid, and protocatechuic acid. It functions as a potent antioxidant and anti-inflammatory agent, demonstrating the ability to scavenge reactive oxygen species, reduce inflammatory markers like TNF-α, and modulate lipid metabolism by downregulating cholesterol biosynthesis genes such as HMGCR. Clinical studies have investigated its potential in improving cardiovascular health, specifically targeting hyperlipidemia and hypertension through mechanisms involving endothelial nitric oxide synthase (eNOS) activation and blood pressure regulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oil palm phenolics.